文章核心观点 - 公司Taro Pharmaceutical Industries Ltd.被指在2024年1月25日的首次公开募股(IPO)中,发布了虚假和误导性的信息 [1][2][3][4] - 公司董事会在2024年4月15日授权提交了一份不完整和误导性的最终代理声明(Proxy),违反了《交易法》第14(a)条和第20(a)条 [3][4] - 公司在代理声明中夸大了并购交易的公平性,隐瞒了BofA Securities的估值分析方法和关键假设等重要信息 [4] 根据目录分类总结 案件概况 - 该诉讼代表所有在公司2024年1月25日IPO中购买或以其他方式获得公司证券的投资者提起集体诉讼 [2] - 投资者被鼓励通过律所网站加入该案件 [2][5] 案件细节 - 公司董事会于2024年1月17日与Sun Pharmaceutical Industries Ltd.签订了并购协议,每股支付43美元的并购对价 [3] - 公司董事会于2024年4月15日授权提交了一份不完整和误导性的最终代理声明 [3][4] - 代理声明中夸大了并购交易的公平性,隐瞒了BofA Securities的估值分析方法和关键假设等重要信息 [4] 后续进展 - 集体诉讼已经提起,投资者可以在2024年11月12日之前申请担任首席原告 [5] - 律所将根据成功与否向法院申请报销垫付费用和律师费用 [6] - 律所是一家全国知名的代表投资者的证券欺诈集体诉讼和股东衍生诉讼的律所,已经为投资者收回了数亿美元 [7]

MILWAUKEE, Sept. 10, 2024 /PRNewswire/ -- Ademi LLP announces that a class action lawsuit has been filed on September 9, 2024 in the United States District Court for the Southern District of New York, captioned Mitchell v. Taro Pharmaceutical Industries Ltd., et al., Case No. 7:24-cv-06818, on behalf of a class of individuals and entities (the "Class") that held securities of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1 ...

Combined entity is better positioned to compete in increasingly competitive generics industry Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun Pharma's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% ...

MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholde ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024 Hawthorne, NY, May 20, 2024 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compare ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cove ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K ...

财务表现 - 净销售额增加220万美元，同比增长1.4%，达到1.589亿美元[3] - 毛利润为6410万美元，占净销售额40.3%，去年同期为8160万美元，占净销售额52.1%[4] - 营业收益/(亏损)为(790)万美元，去年同期为1400万美元，剔除一次性费用影响后为(170)万美元[5] - 净收益为1000万美元，去年同期为1410万美元，每股收益为0.27美元，去年同期为0.37美元，剔除一次性费用影响后净收益为1490万美元，每股收益为0.40美元[6] 费用情况 - 研发费用增加460万美元至1610万美元[4] - 销售、营销、一般及行政费用(SMGA)为5590万美元，包括与搬迁Alchemee业务从加州到纽约相关的一次性过渡费用620万美元，剔除该费用后SMGA为4970万美元，较去年同期减少640万美元[4] 其他财务指标 - 利息及其他财务收益增加900万美元至1090万美元[6] - 汇兑收益为210万美元，去年同期为汇兑费用30万美元，影响为240万美元[6] - 所得税(收益)/费用为(460)万美元，去年同期为税费200万美元[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover ...